---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-035061"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2026-05-14T20:02:06+00:00"
generated_at: "2026-05-14T21:02:47.199909+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sangamo Q1 net loss $31M; cash only into Q3 2026; stock delisted to OTCQB

## Summary
- Q1 2026 net loss $31.0M ($0.08/share) vs $30.6M loss in Q1 2025; revenue dropped to $1.4M from $6.4M.
- Cash and cash equivalents $27.6M as of March 31 – expects to fund operations only into Q3 2026.
- Common stock delisted from Nasdaq, now trading on OTCQB; hearing to appeal delisting scheduled June 9.
- Rolling BLA for Fabry gene therapy ST-920 underway; CMC module completion expected summer 2026 subject to funding.
- 2026 GAAP operating expense guidance $110M-$130M; company warns guidance depends on securing additional funding.

## SEC filing metadata
- accession: 0001628280-26-035061
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2026-05-14T20:02:06+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828026035061/0001628280-26-035061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828026035061/sgmo-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-035061
- JSON: https://secwatch.observer/filing/0001628280-26-035061.json
- Plain text: https://secwatch.observer/filing/0001628280-26-035061.txt

## Key facts
- Earnings Releases
  SANGAMO THERAPEUTICS, INC reported first quarter ended March 31, 2026 results: revenue $1.4 million, net income $31.0 million, EPS $0.08 per share.
  - Period: first quarter ended March 31, 2026
  - Revenue: $1.4 million
  - Net income: $31.0 million
  - EPS: $0.08 per share
  - Result: reported results
  source text: First Quarter 2026 Financial Results Consolidated net loss for the first quarter ended March 31, 2026 was $31.0 million, or $0.08 per share, compared to a consolidated net loss of $30.6 million, or $0.14 per share, for the same period in 2025. Revenues Revenues for the first quarter ended March 31, 2026 were $1.4 million, compared to $6.4 million for the same period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001233/000162828026035061/0001628280-26-035061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.